U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07817212) titled 'ESR1Real World Assessment Prevalence Study' on Sept. 08.
Brief Summary: Many patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer in the first therapy line is endocrine sensitive. For these patients the established 1st line standard therapy is a combination of a CDK4/6 inhibitor and an aromatase inhibitor. This combination therapy is usually given until clinical progression.
Recent studies suggest that a detection of a somatic ESR1 mutation in the ctDNA can be clinically used to prompt an earlier change from the aromatase inhibitor to a selective estrogen rec...